The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Biogen P/E ratio is 21.92. it has decreased in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Biogen’s P/E ratio

## What is Biogen P/E Ratio?

Biogen’s P/E ratio is 21.92, which represents a 24.13% decrease from the same period last year. their average P/E ratio is 26.41 and their 5-year average is 13.18.

## What is Biogen Net EPS?

Biogen’s net earnings for the most recent quarter were 9.85 US dollars, which represents a 21.2% decrease from the same period last year.

## Who are Biogen Competitors?

Based on Jika.io AI model, AbbVie, Affiliated Managers Group, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Eli Lilly and, Pfizer, Banco Santander, S.A. are considered to be Biogen’s competitors because the companies operate within the same industry as Biogen and are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Biogen.

## Who is Biogen’s Biggest competitor?

Biogen’s biggest competitor is AbbVie, based on the AI model of Jika.io. it has a similar market capitalization to Biogen in the industry, it dominates a similar share of the market as Biogen, and it provides and markets very similar services.

## What industry is Biogen in?

Biogen is part of the pharmaceutical industry – General industry and Healthcare.

## Biogen vs AbbVie

Market Cap: Biogen’s Market Cap of 31630702592 is lower than AbbVie Market Cap of 269537296384.

Average Volume: Biogen’s Average Volume of 1.143M is lower than AbbVie Average Volume of 7.245M.

Beta: Biogen’s Beta of 0.42 is lower than AbbVie Beta of 0.81.

Revenue: Biogen’s Revenue of 10.982B is lower than AbbVie Revenue of 56.197B.

Net Income: Biogen’s Net Income of 1.556B is lower than AbbVie Net Income of 11.542B.

Gross Profit: Biogen’s Gross Profit of 8.872B is higher than AbbVie Gross Profit of 38.751B.

Ebitda: Biogen’s Ebitda of 2.35B is lower than AbbVie Ebitda of 23.926B.

P/E Ratio: Biogen’s P/E Ratio of 21.9 is higher than AbbVie P/E Ratio of 21.88.

P/S Ratio: Biogen’s P/S Ratio of 2.94 is lower than AbbVie P/S Ratio of 4.75.

P/B Ratio: Biogen’s P/B Ratio of 2.83 is higher than AbbVie P/B Ratio of 16.55.

P/FCF Ratio: Biogen’s P/FCF Ratio of 11.46 is lower than AbbVie P/FCF Ratio of 12.22.

ROE: Biogen’s ROE of 0.13 is lower than AbbVie ROE of 0.86.

ROA: Biogen’s ROA of 0.06 is lower than AbbVie ROA of 0.09.

Return On Capital Employed: Biogen’s Return On Capital Employed of 0.13 is lower than AbbVie Return On Capital Employed of 0.17.

Gross Profit Margin: Biogen’s Gross Profit Margin of 0.78 is higher than AbbVie Gross Profit Margin of 0.7.

Assets (Total): Biogen’s Assets (Total) of 23.877B is higher than AbbVie Assets (Total) of 146.529B.

Debt (Total): Biogen’s Debt (Total) of 7.604B is lower than AbbVie Debt (Total) of 76.684B.

Shareholders Equity: Biogen’s Shareholders Equity of 10.896B is lower than AbbVie Shareholders Equity of 15.408B.

## Biogen vs Affiliated Managers Group

Market Cap: Biogen’s Market Cap of 31630702592 is higher than Affiliated Managers Group Market Cap of 4601176576.

Average Volume: Biogen’s Average Volume of 1.143M is lower than Affiliated Managers Group Average Volume of 263825.0.

Beta: Biogen’s Beta of 0.42 is lower than Affiliated Managers Group Beta of 1.33.

Revenue: Biogen’s Revenue of 10.982B is lower than Affiliated Managers Group Revenue of 2.412B.

Net Income: Biogen’s Net Income of 1.556B is lower than Affiliated Managers Group Net Income of 565.7M.

Gross Profit: Biogen’s Gross Profit of 8.872B is higher than Affiliated Managers Group Gross Profit of 1.365B.

Ebitda: Biogen’s Ebitda of 2.35B is lower than Affiliated Managers Group Ebitda of 980.4M.

P/E Ratio: Biogen’s P/E Ratio of 21.9 is lower than Affiliated Managers Group P/E Ratio of 9.1.

P/S Ratio: Biogen’s P/S Ratio of 2.94 is higher than Affiliated Managers Group P/S Ratio of 1.92.

P/B Ratio: Biogen’s P/B Ratio of 2.83 is higher than Affiliated Managers Group P/B Ratio of 1.77.

P/FCF Ratio: Biogen’s P/FCF Ratio of 11.46 is lower than Affiliated Managers Group P/FCF Ratio of 4.46.

ROE: Biogen’s ROE of 0.13 is lower than Affiliated Managers Group ROE of 0.21.

ROA: Biogen’s ROA of 0.06 is lower than Affiliated Managers Group ROA of 0.07.

Return On Capital Employed: Biogen’s Return On Capital Employed of 0.13 is higher than Affiliated Managers Group Return On Capital Employed of 0.12.

Gross Profit Margin: Biogen’s Gross Profit Margin of 0.78 is higher than Affiliated Managers Group Gross Profit Margin of 0.57.

Assets (Total): Biogen’s Assets (Total) of 23.877B is lower than Affiliated Managers Group Assets (Total) of 8.876B.

Debt (Total): Biogen’s Debt (Total) of 7.604B is higher than Affiliated Managers Group Debt (Total) of 2.49B.

## Biogen vs Bristol-Myers Squibb

Market Cap: Biogen’s Market Cap of 31630702592 is lower than Bristol-Myers Squibb Market Cap of 162276950016.

Average Volume: Biogen’s Average Volume of 1.143M is lower than Bristol-Myers Squibb Average Volume of 14.478M.

Beta: Biogen’s Beta of 0.42 is lower than Bristol-Myers Squibb Beta of 0.48.

Revenue: Biogen’s Revenue of 10.982B is lower than Bristol-Myers Squibb Revenue of 46.385B.

Net Income: Biogen’s Net Income of 1.556B is lower than Bristol-Myers Squibb Net Income of 7.014B.

Gross Profit: Biogen’s Gross Profit of 8.872B is higher than Bristol-Myers Squibb Gross Profit of 36.445B.

Ebitda: Biogen’s Ebitda of 2.35B is higher than Bristol-Myers Squibb Ebitda of 18.784B.

P/E Ratio: Biogen’s P/E Ratio of 21.9 is lower than Bristol-Myers Squibb P/E Ratio of 27.03.

P/S Ratio: Biogen’s P/S Ratio of 2.94 is lower than Bristol-Myers Squibb P/S Ratio of 3.57.

P/B Ratio: Biogen’s P/B Ratio of 2.83 is lower than Bristol-Myers Squibb P/B Ratio of 5.31.

P/FCF Ratio: Biogen’s P/FCF Ratio of 11.46 is higher than Bristol-Myers Squibb P/FCF Ratio of 11.08.

ROE: Biogen’s ROE of 0.13 is lower than Bristol-Myers Squibb ROE of 0.18.

ROA: Biogen’s ROA of 0.06 is lower than Bristol-Myers Squibb ROA of 0.06.

Return On Capital Employed: Biogen’s Return On Capital Employed of 0.13 is lower than Bristol-Myers Squibb Return On Capital Employed of 0.13.

Gross Profit Margin: Biogen’s Gross Profit Margin of 0.78 is lower than Bristol-Myers Squibb Gross Profit Margin of 0.8.

Assets (Total): Biogen’s Assets (Total) of 23.877B is higher than Bristol-Myers Squibb Assets (Total) of 109.314B.

Debt (Total): Biogen’s Debt (Total) of 7.604B is higher than Bristol-Myers Squibb Debt (Total) of 44.553B.

Shareholders Equity: Biogen’s Shareholders Equity of 10.896B is lower than Bristol-Myers Squibb Shareholders Equity of 36.006B.

## Biogen vs Gilead Sciences

Market Cap: Biogen’s Market Cap of 31630702592 is lower than Gilead Sciences Market Cap of 78682865664.

Average Volume: Biogen’s Average Volume of 1.143M is lower than Gilead Sciences Average Volume of 7.973M.

Beta: Biogen’s Beta of 0.42 is higher than Gilead Sciences Beta of 0.38.

Revenue: Biogen’s Revenue of 10.982B is lower than Gilead Sciences Revenue of 27.305B.

Net Income: Biogen’s Net Income of 1.556B is lower than Gilead Sciences Net Income of 6.225B.

Gross Profit: Biogen’s Gross Profit of 8.872B is higher than Gilead Sciences Gross Profit of 20.704B.

Ebitda: Biogen’s Ebitda of 2.35B is higher than Gilead Sciences Ebitda of 11.353B.

P/E Ratio: Biogen’s P/E Ratio of 21.9 is higher than Gilead Sciences P/E Ratio of 17.52.

P/S Ratio: Biogen’s P/S Ratio of 2.94 is higher than Gilead Sciences P/S Ratio of 2.87.

P/B Ratio: Biogen’s P/B Ratio of 2.83 is lower than Gilead Sciences P/B Ratio of 3.95.

P/FCF Ratio: Biogen’s P/FCF Ratio of 11.46 is lower than Gilead Sciences P/FCF Ratio of 7.91.

ROE: Biogen’s ROE of 0.13 is lower than Gilead Sciences ROE of 0.22.

ROA: Biogen’s ROA of 0.06 is lower than Gilead Sciences ROA of 0.07.

Return On Capital Employed: Biogen’s Return On Capital Employed of 0.13 is lower than Gilead Sciences Return On Capital Employed of 0.13.

Gross Profit Margin: Biogen’s Gross Profit Margin of 0.78 is higher than Gilead Sciences Gross Profit Margin of 0.76.

Assets (Total): Biogen’s Assets (Total) of 23.877B is lower than Gilead Sciences Assets (Total) of 67.952B.

Debt (Total): Biogen’s Debt (Total) of 7.604B is higher than Gilead Sciences Debt (Total) of 26.695B.

Shareholders Equity: Biogen’s Shareholders Equity of 10.896B is lower than Gilead Sciences Shareholders Equity of 21.069B.

## About Biogen

Biogen Inc. develops, develops, manufactures and delivers therapies for the treatment of neurological and neurodegenerative diseases. the company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), SPINRAZA for spinal muscular atrophy and FUMADERM for plaque psoriasis. it also provides BENEPALI, an etanercept biosimilar reference ENBREL; ADUHELM for the treatment of Alzheimer’s disease; IMRALDI, an adalimumab biosimilar reference HUMIRA; and FLIXABI, an infliximab biosimilar reference REMICADE. in addition, the company offers RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin’s lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. further, BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 for Alzheimer’s disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100 and BIIB110 for neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB104 for neuropsychiatry; BIIB059 for neuroimmune disorders; BIIB093 and BIIB074 for neuropsychiatric pain; and BYOOVIZ, BIIB800 and SB15 biosimilars, which are under development. the company has agreements with Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc. and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.